Peter J. Mariani Sells 10,649 Shares of AxoGen, Inc. (NASDAQ:AXGN) Stock

AxoGen, Inc. (NASDAQ:AXGNGet Rating) CFO Peter J. Mariani sold 10,649 shares of the firm’s stock in a transaction dated Wednesday, November 16th. The stock was sold at an average price of $11.88, for a total transaction of $126,510.12. Following the completion of the transaction, the chief financial officer now owns 29,698 shares in the company, valued at $352,812.24. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

AxoGen Stock Up 1.8 %

AXGN stock opened at $11.73 on Friday. AxoGen, Inc. has a 52 week low of $6.87 and a 52 week high of $13.66. The company has a market capitalization of $496.06 million, a price-to-earnings ratio of -17.25 and a beta of 0.55. The firm’s 50-day moving average is $11.50 and its two-hundred day moving average is $10.10. The company has a current ratio of 4.35, a quick ratio of 3.54 and a debt-to-equity ratio of 0.65.

Institutional Trading of AxoGen

Hedge funds and other institutional investors have recently made changes to their positions in the stock. OLD National Bancorp IN raised its position in shares of AxoGen by 7.3% during the 1st quarter. OLD National Bancorp IN now owns 19,131 shares of the medical equipment provider’s stock worth $152,000 after buying an additional 1,306 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in shares of AxoGen during the 2nd quarter worth about $100,000. Russell Investments Group Ltd. raised its position in shares of AxoGen by 53.9% during the 1st quarter. Russell Investments Group Ltd. now owns 30,012 shares of the medical equipment provider’s stock worth $237,000 after buying an additional 10,515 shares in the last quarter. Granite Point Capital Management L.P. raised its position in shares of AxoGen by 30.6% during the 1st quarter. Granite Point Capital Management L.P. now owns 103,208 shares of the medical equipment provider’s stock worth $819,000 after buying an additional 24,198 shares in the last quarter. Finally, William Blair Investment Management LLC raised its position in shares of AxoGen by 0.6% during the 2nd quarter. William Blair Investment Management LLC now owns 1,638,905 shares of the medical equipment provider’s stock worth $13,423,000 after buying an additional 10,437 shares in the last quarter. 76.01% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Canaccord Genuity Group lifted their price objective on shares of AxoGen from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, November 9th. StockNews.com upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $15.00 price objective on shares of AxoGen in a research report on Friday, November 11th.

About AxoGen

(Get Rating)

AxoGen, Inc, together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Further Reading

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.